Skip to content
FY'25FY'24FY'23FY'22
Efficiency
Asset turnover0.6×0.4×+0.1×0.3×+0.1×
Liquidity
Current ratio2.3×-1.9×4.2×+0.3×3.9×-0.2×4.1×-1.6×
Quick ratio2.1×-1.8×3.9×+0.3×3.7×-0.2×3.9×-1.5×
Cash ratio0.7×-0.8×1.5×+0.9×0.7×-0.9×1.6×-3.1×
Leverage
Debt-to-equity0.2×0.0×0.1×-0.2×0.3×+0.1×0.2×+0.1×
Debt-to-assets0.1×0.0×0.1×0.0×0.1×+0.1×0.0×
Valuation
Market capitalization$2.26B-80.6%$11.61B+28.7%$9.03B-20.7%$11.38B+44.9%
Enterprise value$1.66B-84.5%$10.72B+20.9%$8.86B-15.5%$10.49B+80.9%
Price / sales7.3×-4.9×12.2×+1.0×
Price / book-5.6×7.6×-2.9×10.5×-19.1×29.6×+21.1×
EV / sales0.8×7.1×-4.1×11.2×+3.0×

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where do Sarepta Therapeutics, Inc.'s ratios come from?
Every ratio is computed from Sarepta Therapeutics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.